Navigation Links
Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib
Date:10/7/2010

EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that management will host a teleconference to provide a status update on its New Drug Application (NDA) for carfilzomib.  Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-585-4405 and using the passcode 28119641. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 28119641# approximately one hour after the teleconference concludes. The replay will be available through October 21, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (s
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
2. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
3. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
4. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
5. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
6. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
8. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
9. Transcept Pharmaceuticals to Present at BIO Investor Forum
10. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
11. Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:8/31/2015)... ... 01, 2015 , ... The PT Outcomes Registry is an organized system for ... patients. The Registry is being developed by the American Physical Therapy Association (APTA). , ... be selected to contribute FOTO Outcomes measures as one of the primary global outcomes ...
(Date:8/31/2015)... GA (PRWEB) , ... August 31, 2015 , ... Sculpted ... one of Atlanta’s Women of Power and Influence by Modern Luxury’s The Atlantan Magazine. ... for the business as well as Kathy King. Her idea and vision to ...
(Date:8/31/2015)... ... 2015 , ... Dental clinicians from Newcastle University, United Kingdom, ... learn more about its integrated approach to diabetes care. , Philip Preshaw, BDS, ... Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research Clinical ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article based on a ... addressed the topic of treating back pain caused by a disrupted disk by using ... slightly improve physical function in patients suffering from a herniated disk, the level of ...
(Date:8/31/2015)... ... ... The Lisle family law firm of Momkus McCluskey, LLC is ... to earn a “Leading Lawyers” distinction. , The “Leading Lawyers” distinction ... The nomination process is based on statewide peer survey nominations and the approval of ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) ... myeloid leukemia, researchers were able to more accurately predict ... remission, and which ones would respond well to standard ... Memorial Sloan-Kettering Cancer Center in New York City analyzed ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) -- People ... a genetic predisposition to be overweight, compared to those who ... The findings don,t prove that the exercise is the ... something else could explain why those who walked were thinner, ...
... meditating for years thickens the brain (in a good ... a further report by UCLA researchers suggests yet another ... at the UCLA Laboratory of Neuro Imaging, and colleagues, ... gyrification ("folding" of the cortex, which may allow the ...
... discrimination is enough to depress anyone, but African-American men ... stoicism and emotional control experience more depression symptoms, according ... at Chapel Hill. The study, "Taking It Like ... Racial DiscriminationDepressive Symptoms Association Among African-American Men," was published ...
... millions of molecules in a drop of a patient,s blood ... or a drug ferry that doesn,t release its toxic contents ... nanotechnologies could be game changers in how we diagnose, monitor ... Engineering at the California Institute of Technology, and a member ...
... identify people infected with hepatitis C virus (HCV) ... new report published in Clinical Infectious Diseases ... reducing HCV-related mortality and morbidity, however, will require ... testing but also linking those infected with the ...
Cached Medicine News:Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 2Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 3Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 4Health News:Brisk Daily Walk Could Counter 'Obesity Genes' 2Health News:Evidence builds that meditation strengthens the brain, UCLA researchers say 2Health News:Hiding emotions may exacerbate depression among black men who confront racial discrimination 2Health News:Fighting cancer with nanotechnology 2Health News:Broader screening for hepatitis C would be cost effective, study suggests 2
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: